jamanetwork.com/journals/ja...
A recent study concludes that Enzalutamide is slightly more beneficial if used before Abiraterone. This is contrary to other studies which some of you have posted recently.
“Findings In this cohort study of 5779 patients with mCRPC from the US Department of Veterans Affairs health care system from 2014 to 2022, initiation of enzalutamide was associated with small but statistically significant improvements in survival times compared with initiation of abiraterone acetate, with more prominent improvements in short-term outcomes and in patient subgroups with less aggressive prostate cancer.”